Holen Sie sich die Stockscreener-App
1.80
9.45%
0.16
Schlusskurs vom Vortag:
$1.64
Offen:
$1.69
24-Stunden-Volumen:
434.52K
Relative Volume:
0.67
Marktkapitalisierung:
$75.98M
Einnahmen:
$19.94M
Nettoeinkommen (Verlust:
$-37.37M
KGV:
-1.4173
EPS:
-1.27
Netto-Cashflow:
$-33.38M
1W Leistung:
-6.99%
1M Leistung:
-37.02%
6M Leistung:
-64.10%
1J Leistung:
-24.26%
1-Tages-Spanne:
$1.63
$1.85
1-Wochen-Bereich:
$1.58
$1.97
52-Wochen-Spanne:
$1.58
$8.1939
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Firmenname
Werewolf Therapeutics Inc
Sektor
Branche
Telefon
617-952-0555
Adresse
200 TALCOTT AVENUE, WATERTOWN
Vergleichen Sie HOWL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| HOWL | 1.795 | 75.98M | 19.94M | -37.37M | -33.38M | -1.27 |
| VRTX | 449.81 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.23 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.98 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.53 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-03 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-24 | Eingeleitet | Wedbush | Outperform |
| 2023-06-06 | Fortgesetzt | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-25 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-25 | Eingeleitet | Jefferies | Buy |
| 2021-05-25 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - The Manila Times
Werewolf Therapeutics stock hits 52-week low at $1.62 - Investing.com India
Werewolf Therapeutics stock hits 52-week low at $1.62 By Investing.com - Investing.com Canada
Werewolf Therapeutics stock holds buy rating amid investor concerns over cytokine therapies By Investing.com - Investing.com Canada
Werewolf Therapeutics' (HOWL) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Equities Analysts Set Expectations for HOWL FY2024 Earnings - MarketBeat
Werewolf Therapeutics' SWOT analysis: oncology biotech's stock potential amid clinical progress - Investing.com Australia
What is HC Wainwright's Forecast for HOWL Q1 Earnings? - MarketBeat
Werewolf Therapeutics reports promising trial data for cancer drug By Investing.com - Investing.com South Africa
Werewolf Therapeutics Inc (HOWL) Quarterly 10-Q Report - Quartz
Werewolf Therapeutics reports promising trial data for cancer drug - Investing.com
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Presents Preclinical and Clinical - GlobeNewswire
Werewolf's WTX-330 Shows Promise in Phase 1 Trial: Melanoma Patient Responds to Novel IL-12 Therapy | HOWL Stock News - StockTitan
Werewolf Therapeutics Reports Breakthrough Cancer Trial Results Despite $16.7M Loss | HOWL Stock News - StockTitan
Werewolf Therapeutics announces IL-10 Indukine development candidate for inflammatory bowel disease - BioWorld Online
Werewolf Therapeutics expands pipeline with new IBD candidate By Investing.com - Investing.com South Africa
Werewolf Therapeutics expands pipeline with new IBD candidate - Investing.com
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases - The Manila Times
Werewolf Therapeutics Announces Promising New Development - GlobeNewswire
WisdomTree Inc (NYSE: WT): Blank Check On Growth? - Stocks Register
Werewolf To Provide Clinical Update On WTX-330 - RTTNews
Werewolf Therapeutics Inc (NASDAQ: HOWL) Could Pass $12 In One Year Stock Forecast - Stocks Register
Social Security Just Released the 2025 COLA. Here's What It Means for Those Receiving Spousal Benefits. - Yahoo! Voices
Could Buying Apple Stock Today Set You Up for Life? - Yahoo! Voices
Is Summit Therapeutics Inc. (SMMT) the Best QQQ Stock to Buy According to Analysts? - Yahoo Finance
Lyft is working on a ‘service animal opt-in feature’ for passengers - Yahoo! Voices
Hammond packaging facility to get $35M upgrade - Yahoo! Voices
2 Game-Changing Artificial Intelligence (AI) Stocks to Buy Right Now (Hint: Not Nvidia) - Yahoo! Voices
Poland’s stunning success should be discomforting for Britain - Yahoo! Voices
Every UPS Investor Should Keep an Eye on This Number - Yahoo! Voices
Billionaire Philippe Laffont Just Increased His Position by 139% in This Data Center Opportunity (Hint: It's Not Nvidia) - Yahoo! Voices
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance
ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance
Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Cut the state to get growing - Yahoo! Voices
‘It’s huge’: Striking Boeing workers near deal - Yahoo! Voices
National Association of Black Accountants’ St. Louis Chapter honors 50 years of community impact - Yahoo! Voices
Voya Financial Reports $341 Billion AUM Milestone - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
mRNA licensing agreements surge 800% amid GSK lawsuits - Yahoo Finance
State Street Corp's Strategic Reduction in Viridian Therapeutics Inc - Yahoo Finance
State Street Corp's Strategic Reduction in Viking Therapeutics Holdings - Yahoo Finance
Nvidia to be the first company to hit $4T market cap: Lumida CEO - Yahoo Finance
LGT incorporates its Barcelona digital hub - Yahoo News
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar? - Yahoo Finance
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings - Yahoo Finance
NantHealth (NASDAQ:NH) Coverage Initiated by Analysts at StockNews.com - Defense World
StockNews.com Downgrades Nomad Foods (NYSE:NOMD) to Hold - Defense World
Microsoft said it lost weeks of security logs for its customers' cloud products - Yahoo! Voices
Finanzdaten der Werewolf Therapeutics Inc-Aktie (HOWL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):